Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744206 | 1.00 | NPC1 (0.54) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL23744062 | 0.94 | NPC1 (0.47) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL23744456 | 0.91 | CHRM4 (0.47) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL23744655 | 0.91 | CHRM4 (0.47) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL23744179 | 0.90 | CHRM2 (0.47) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL23744637 | 0.90 | CHRM4 (0.45) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL23744703 | 0.89 | CHRM2 (0.49) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL23744576 | 0.86 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL23744207 | 0.86 | HCAR2 (0.48) | NPC1RAB9AHCAR2CHRM2CHRM1 | |
| SCHEMBL26429428 | 0.86 | HCAR2 (0.48) | NPC1RAB9AHCAR2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | NPC1 1236/4885RAB9A 3190/4885HCAR2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.